Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs
NCT ID: NCT04924946
Last Updated: 2021-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-06-01
2021-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intra-abdominal Hypertension in Critically Ill Patients
NCT02514135
French and EuRopean Outcome Registry in Intensive Care Unit
NCT01367093
Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)
NCT04948242
Severe Hypoxemia : Prevalence, Treatment and Outcome
NCT02722031
Anti-pyretic Therapy in Critically Ill Adults
NCT01173367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs
* Time to monitor blood pressure values in target targets
* Need for administration of another antihypertensive drug
* Disappearance of organ failure attributable to hypertension
* Weaning from an extra-renal purification
* Weaning from mechanical ventilation
* Improved kidney function
* Iatrogenic hypotension
* Need for suspension of treatment
* Other side effect
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to an intensive care unit
* Patient having presented a state of circulatory shock, defined by the need for continuous administration of a vasopressive amine for at least one hour, among: Noradrenaline, Adrenaline
* In whom the introduction of drug treatment for antihypertensive purposes is decided
Exclusion Criteria
* Patient who has already received at least one anti-hypertensive drug during his stay in intensive care
* Cerebro-injured patient, proven or suspected cerebral edema, head trauma \<1 month, decrease in cerebral perfusion measured
* Proven or suspected active bleeding
* Patient refusal of participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Victor Dupouy Hospital
Argenteuil, , France
Intensive Care Avicenne Hsopital
Bobigny, , France
Intensive Care Louis Mourier Hospital
Colombes, , France
Intensive Care Longjumeau Hospital
Longjumeau, , France
Intensive Care Bichat Hospital
Paris, , France
Intensive Care René Dubos Hospital
Pontoise, , France
Intensive Care Tours Hospital
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP191137
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.